These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 20958842)

  • 1. A placebo-controlled trial of atomoxetine in marijuana-dependent individuals with attention deficit hyperactivity disorder.
    McRae-Clark AL; Carter RE; Killeen TK; Carpenter MJ; White KG; Brady KT
    Am J Addict; 2010; 19(6):481-9. PubMed ID: 20958842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atomoxetine treatment of attention-deficit/hyperactivity disorder in young adults with assessment of functional outcomes: a randomized, double-blind, placebo-controlled clinical trial.
    Durell TM; Adler LA; Williams DW; Deldar A; McGough JJ; Glaser PE; Rubin RL; Pigott TA; Sarkis EH; Fox BK
    J Clin Psychopharmacol; 2013 Feb; 33(1):45-54. PubMed ID: 23277268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder.
    Simpson D; Plosker GL
    Drugs; 2004; 64(2):205-22. PubMed ID: 14717619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in Germany.
    Dittmann RW; Schacht A; Helsberg K; Schneider-Fresenius C; Lehmann M; Lehmkuhl G; Wehmeier PM
    J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):97-110. PubMed ID: 21488751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial.
    Adler LA; Spencer T; Brown TE; Holdnack J; Saylor K; Schuh K; Trzepacz PT; Williams DW; Kelsey D
    J Clin Psychopharmacol; 2009 Feb; 29(1):44-50. PubMed ID: 19142107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spotlight on atomoxetine in adults with attention-deficit hyperactivity disorder.
    Simpson D; Plosker GL
    CNS Drugs; 2004; 18(6):397-401. PubMed ID: 15089111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationships Between Functional Outcomes and Symptomatic Improvement in Atomoxetine-Treated Adult Patients with Attention-Deficit/Hyperactivity Disorder: Post Hoc Analysis of an Integrated Database.
    De Bruyckere K; Bushe C; Bartel C; Berggren L; Kan CC; Dittmann RW
    CNS Drugs; 2016 Jun; 30(6):541-58. PubMed ID: 27224994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder.
    Harfterkamp M; van de Loo-Neus G; Minderaa RB; van der Gaag RJ; Escobar R; Schacht A; Pamulapati S; Buitelaar JK; Hoekstra PJ
    J Am Acad Child Adolesc Psychiatry; 2012 Jul; 51(7):733-41. PubMed ID: 22721596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: a 6-week, randomized, placebo-controlled, double-blind trial in Russia.
    Martenyi F; Zavadenko NN; Jarkova NB; Yarosh AA; Soldatenkova VO; Bardenstein LM; Kozlova IA; Neznanov NG; Maslova OI; Petrukhin AS; Sukchotina NK; Zykov VP
    Eur Child Adolesc Psychiatry; 2010 Jan; 19(1):57-66. PubMed ID: 19568826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder.
    Bangs ME; Hazell P; Danckaerts M; Hoare P; Coghill DR; Wehmeier PM; Williams DW; Moore RJ; Levine L;
    Pediatrics; 2008 Feb; 121(2):e314-20. PubMed ID: 18245404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term treatment with atomoxetine for attention-deficit/hyperactivity disorder symptoms in children and adolescents with autism spectrum disorder: an open-label extension study.
    Harfterkamp M; Buitelaar JK; Minderaa RB; van de Loo-Neus G; van der Gaag RJ; Hoekstra PJ
    J Child Adolesc Psychopharmacol; 2013 Apr; 23(3):194-9. PubMed ID: 23578015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, double-blind, placebo-controlled clinical trial on once-daily atomoxetine in Taiwanese children and adolescents with attention-deficit/hyperactivity disorder.
    Gau SS; Huang YS; Soong WT; Chou MC; Chou WJ; Shang CY; Tseng WL; Allen AJ; Lee P
    J Child Adolesc Psychopharmacol; 2007 Aug; 17(4):447-60. PubMed ID: 17822340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlates of alcohol use in adults with ADHD and comorbid alcohol use disorders: exploratory analysis of a placebo-controlled trial of atomoxetine.
    Wilens TE; Adler LA; Tanaka Y; Xiao F; D'Souza DN; Gutkin SW; Upadhyaya HP
    Curr Med Res Opin; 2011 Dec; 27(12):2309-20. PubMed ID: 22029549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis.
    Cheng JY; Chen RY; Ko JS; Ng EM
    Psychopharmacology (Berl); 2007 Oct; 194(2):197-209. PubMed ID: 17572882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of atomoxetine for first-line treatment of newly diagnosed, treatment-naïve children and adolescents with attention deficit/hyperactivity disorder.
    Montoya A; Hervas A; Cardo E; Artigas J; Mardomingo MJ; Alda JA; Gastaminza X; García-Polavieja MJ; Gilaberte I; Escobar R
    Curr Med Res Opin; 2009 Nov; 25(11):2745-54. PubMed ID: 19785510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of atomoxetine hydrochloride in Korean adults with attention-deficit hyperactivity disorder.
    Lee SI; Song DH; Shin DW; Kim JH; Lee YS; Hwang JW; Park TW; Yook KH; Lee JI; Bahn GH; Hirata Y; Goto T; Takita Y; Takahashi M; Lee S; Treuer T
    Asia Pac Psychiatry; 2014 Dec; 6(4):386-96. PubMed ID: 25345739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between atomoxetine plasma concentration, treatment response and tolerability in attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder.
    Hazell P; Becker K; Nikkanen EA; Trzepacz PT; Tanaka Y; Tabas L; D'Souza DN; Witcher J; Long A; Ponsler G; Dittmann RW
    Atten Defic Hyperact Disord; 2009 Dec; 1(2):201-10. PubMed ID: 20234828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized, controlled trial of atomoxetine for attention-deficit/hyperactivity disorder in adolescents with substance use disorder.
    Thurstone C; Riggs PD; Salomonsen-Sautel S; Mikulich-Gilbertson SK
    J Am Acad Child Adolesc Psychiatry; 2010 Jun; 49(6):573-82. PubMed ID: 20494267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atomoxetine as an adjunct therapy in the treatment of co-morbid attention-deficit/hyperactivity disorder in children and adolescents with bipolar I or II disorder.
    Chang K; Nayar D; Howe M; Rana M
    J Child Adolesc Psychopharmacol; 2009 Oct; 19(5):547-51. PubMed ID: 19877979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders.
    Wilens TE; Adler LA; Weiss MD; Michelson D; Ramsey JL; Moore RJ; Renard D; Brady KT; Trzepacz PT; Schuh LM; Ahrbecker LM; Levine LR;
    Drug Alcohol Depend; 2008 Jul; 96(1-2):145-54. PubMed ID: 18403134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.